权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Analysis of the role of the SWI/SNF complex in tumor suppression

SWI/SNF复合物抑制肿瘤的作用分析

基本信息

批准号：
8579030
负责人：
CHARLES ROBERTS
金额：
$ 35.93万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8579030
关键词：
ATP Hydrolysis Affect Bladder Breast Cancer Etiology Cancer cell line Cell Line Chromatin Chromatin Remodeling Factor Chromatin Structure Colon Colorectal Cancer Complex DNA DNA Binding Data Development EZH2 gene Epigenetic Process Event Frequencies Gene Expression Gene Mutation Generations Genes Genetic Transcription Genetically Engineered Mouse Goals Growth Histone H3 Human Impairment Individual Kidney Knockout Mice Laboratories Laboratory Research Liver Lung Lysine Malignant - descriptor Malignant Childhood Neoplasm Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of pancreas Malignant neoplasm of urinary bladder Modeling Molecular Mus Mutate Mutation Non-Small-Cell Lung Carcinoma Nucleosomes Ovarian Ovary Pancreas Pancreatic carcinoma Pathway interactions Polycomb Positioning Attribute Publications Recurrence Renal carcinoma Residual state Rhabdoid Tumor Role SMARCA4 gene SMARCB1 gene Site-Directed Mutagenesis Skin Stomach Testing Therapeutic Translations Tumor Suppression Tumor Suppressor Proteins Uterus base cancer cell cancer genome chromatin remodeling clinically relevant driving force exome sequencing genome sequencing histone modification human disease in vivo inhibitor/antagonist insight interest malignant breast neoplasm malignant stomach neoplasm melanoma mouse model mutant novel programs public health relevance research study therapeutic target tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Emerging data implicate the SWI/SNF chromatin remodeling complex as a major tumor suppressor. Over the past [two years], numerous cancer genome sequencing studies have revealed that at least six subunits of the complex are specifically inactivated at high frequency in a variety of human cancers including those of ovary, breast, kidney, lung, pancreas, uterus, bladder, stomach, colon, liver [and skin]. The SWI/SNF complex includes both core and lineage-specific subunits and utilizes the energy of ATP to modulate chromatin structure. My laboratory has demonstrated a potent and bona fide tumor suppressor role for one of the subunits through generation of a knockout mouse model. Providing some insight into mechanism, we have recently established the existence of epigenetic antagonism between SWI/SNF and Polycomb complexes. However, the contributions of the SWI/SNF complex to chromatin structure in vivo and the reasons why each subunit is associated with distinct cancer spectra remain poorly understood. Given the unique chromatin targeting and modification domains found in each subunit, we hypothesize that oncogenesis occurs due to differential mistargeting of residual SWI/SNF complexes and impairment of their chromatin remodeling activity. We further hypothesize that SWI/SNF subunit mutations cause disruption of lineage-specific gene expression programs arising from imbalanced epigenetic antagonism with the Polycomb PRC2 complex. Via the following specific aims, our goals are to determine how the subunits of the SWI/SNF complex contribute to chromatin structure, to establish the mechanism by which mutation of the tumor suppressor subunits drives cancer formation, to determine the extent of epigenetic antagonism between the tumor suppressor subunits and the PRC2 complex, and to identify novel and effective therapeutic targets for SWI/SNF mutant cancers: Aim 1: How does loss of individual SWI/SNF tumor suppressor subunits affect the DNA binding, chromatin remodeling activity, and integrity of the SWI/SNF complex, and how does their loss affect gene expression? Aim 2: What is the role of the residual SWI/SNF complex in cancers driven by mutation of SWI/SNF tumor suppressor subunits? Aim 3: What is the relationship between Polycomb complexes and cancers that are driven by SWI/SNF mutations? Significance: Given the increasingly wide spectrum of cancers being found to contain mutations in SWI/SNF subunits, the complex now emerges as having major relevance for human disease. Testing our hypotheses via the proposed specific aims has the potential to elucidate the function of the normal SWI/SNF complex, establish the mechanisms by which mutation of SWI/SNF tumor suppressor subunits drive cancer formation, and identify therapeutic targets for the wide variety of SWI/SNF mutant cancers.

描述（由申请人提供）：新数据表明 SWI/SNF 染色质重塑复合物是主要的肿瘤抑制因子。在过去[两年]中，大量癌症基因组测序研究表明，该复合物的至少六个亚基在多种人类癌症中以高频率特异性失活，包括卵巢癌、乳腺癌、肾癌、肺癌、胰腺癌、子宫癌、膀胱癌、胃癌、结肠癌、肝癌[和皮肤]。 SWI/SNF 复合体包括核心亚基和谱系特异性亚基，并利用 ATP 的能量来调节染色质结构。我的实验室通过生成基因敲除小鼠模型，证明了其中一个亚基具有有效且真正的肿瘤抑制作用。通过对机制的一些深入了解，我们最近确定了 SWI/SNF 和 Polycomb 复合物之间存在表观遗传拮抗作用。然而，SWI/SNF 复合物对体内染色质结构的贡献以及每个亚基与不同癌症谱相关的原因仍然知之甚少。鉴于每个亚基中发现的独特染色质靶向和修饰域，我们假设肿瘤发生是由于残留 SWI/SNF 复合物的差异性错误靶向及其染色质重塑活性受损而发生的。我们进一步假设 SWI/SNF 亚基突变会因与 Polycomb PRC2 复合物的不平衡表观遗传拮抗作用而导致谱系特异性基因表达程序的破坏。通过以下具体目标，我们的目标是确定SWI/SNF复合物的亚基如何影响染色质结构，建立抑癌亚基突变驱动癌症形成的机制，确定抑癌亚基与PRC2复合物之间表观遗传拮抗的程度，并确定SWI/SNF突变癌症的新型有效治疗靶点：目标1：单个 SWI/SNF 肿瘤抑制亚基会影响 DNA 结合、染色质重塑活性和 SWI/SNF 复合物的完整性，它们的丢失如何影响基因表达？目标 2：残留的 SWI/SNF 复合物在 SWI/SNF 抑癌亚基突变驱动的癌症中发挥什么作用？目标 3：Polycomb 复合物与 SWI/SNF 突变驱动的癌症之间有何关系？意义：鉴于越来越多的癌症被发现含有 SWI/SNF 亚基突变，该复合物现在看来与人类疾病具有重要相关性。通过提出的具体目标测试我们的假设有可能阐明正常 SWI/SNF 复合物的功能，建立 SWI/SNF 肿瘤抑制亚基突变驱动癌症形成的机制，并确定各种 SWI/SNF 突变癌症的治疗靶点。